Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effective dose of remimazolam tosilate for suppressing airway insertion responses in different genders
ChiCTR2100048631Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Blood pressure and Heart rate. Started Feb 2021; status: completed.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ChiCTR2100048631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048631.